QUOTE AND NEWS
Benzinga  Apr 16  Comment 
In a report published Wednesday, Canaccord Genuity analyst John Newman assumed coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with a Buy rating and $42.00 price target. In the report, Canaccord Genuity noted, “We recommend buying NPSP on...
DailyFinance  Mar 31  Comment 
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the 13th Annual Needham Healthcare Conference in New York on Tuesday, April 8, 2014 at 8:00 a.m. ET. The presentation will be available as a live webcast with a replay...
Benzinga  Mar 25  Comment 
Analysts at Imperial Capital initiated coverage on shares of FireEye (NASDAQ: FEYE) with an “in-line” rating. The target price for FireEye is set to $68. FireEye's shares closed at $63.50 yesterday. Goldman Sachs initiated coverage on...
Stock Blog Hub  Mar 15  Comment 
Yesterday, I was on Komodo Island, Indonesia, as part of The Oxford Club’s Chairman’s Circle cruise to Australia and Indonesia. We saw the famed Komodo dragons, which are some of the most lethal animals in the world. When they bite, they...
DailyFinance  Feb 26  Comment 
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 11, 2014 at 9:00 a.m. ET. The presentation will be available as a live webcast with a replay...
SeekingAlpha  Feb 25  Comment 
By ONeil Trader: Executive summary: NPS Pharmaceuticals' (NPSP) successful launch of Gattex and plans for international expansion put the company on a path to significant growth. Natpara is expected to be approved by the end of 2014...
SeekingAlpha  Feb 20  Comment 
NPS Pharmaceuticals, Inc. (NPSP) Q4 2013 Earnings Conference Call February 18, 2014 5:00 PM ET Executives Susan Mesco – Senior Director, IR and Corporate Communications Dr. Francois Nader – President and CEO Eric Pauwels –...
StreetInsider.com  Feb 19  Comment 
UPGRADES Macquarie upgrades Fluor (NYSE: FLR) from Neutral to Outperform and moves its price target from $70 up to $98. Goldman Sachs boosts Actavis (NYSE: ACT) from Neutral to Buy, while adjusting its price target from $185 up to $250. Click...
Benzinga  Feb 19  Comment 
In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Buy to Hold, but reiterated the $38.00 price target. In the report, Jefferies noted, “FY14 guidance/4Q13 sales of...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki